M&A Deal Summary

Nuvation Bio Acquires AnHeart

On March 25, 2024, Nuvation Bio acquired life science company AnHeart

Acquisition Highlights
  • This is Nuvation Bio’s 1st transaction in the Life Science sector.
  • This is Nuvation Bio’s 1st transaction in the United States.
  • This is Nuvation Bio’s 1st transaction in New York.

M&A Deal Summary
Date 2024-03-25
Target AnHeart
Sector Life Science
Buyer(s) Nuvation Bio
Deal Type Add-on Acquisition
Advisor(s) Davis Polk & Wardwell
Fangda Partners
Walkers Global (Legal)

Target

AnHeart

New York, New York, United States
AnHeart is a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer. AnHeart’s lead investigational therapy, taletrectinib, is a next-generation ROS1 inhibitor currently in pivotal Phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart is based in New York, New York.

Search 201,157 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Nuvation Bio

New York, New York, United States
Category Company
Founded 2018
Sector Life Science
Employees167
DESCRIPTION

Nuvation Bio is an oncology drug development company pursuing first-in-class and best-in-class anti-cancer agents. Nuvation Bio was founded in 2018 and is based in New York City.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (New York) 1 of 1
Country (United States) 1 of 1
Year (2024) 1 of 1
Mergr

Product

Company

Legal